Sorry, you need to enable JavaScript to visit this website.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for AlertsDetails
Title
Grant Type
Focus Area
Country
Application Due Date
BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Oncology Japan
Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
Release Date:
Review Process: Pfizer Internal
Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
Release Date:
Partner: Sumitomo Pharma
Review Process: Pfizer Internal
Education Oncology USA
Title
Grant Type
Focus Area
Country
Application Due Date
Improvement of Treatment Environment for Advanced / Recurrent Breast Cancer
Release Date:
Review Process: Pfizer Internal
Education Oncology Japan
Improving RCC Patient Outcomes
Release Date:
Review Process: Pfizer Internal
Education Oncology France, Germany, Italy, Spain, USA, United Kingdom
Biomarker Testing / Lung Cancer
Release Date:
Review Process: Pfizer Internal
Education Oncology Japan
Employment support / Lung Cancer
Release Date:
Review Process: Pfizer Internal
Education Oncology Japan
Immunotherapy in Urothelial Carcinoma
Release Date:
Partner: Merck KGaA, Darmstadt, Germany
Review Process: Pfizer Internal
Education Oncology All
Pre-clinical and Translational Research in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology Italy
PARP-inhibitor Combination Treatments in Prostate Cancer
Release Date:
Review Process: Pfizer Internal
Education Oncology USA
Knowledge Gaps in Updated Adult Pneumococcal Immunization Recommendations
Release Date:
Review Process: Pfizer Internal
Education Vaccines USA
Establishment of Hospital-Clinic Collaboration Model for Undiagnosed Rheumatic Diseases
Release Date:
Partner: The Japan College of Rheumatology
Review Process: Expert Review Panel
Quality Improvement Inflammation & Immunology Japan
COVID-19 Vaccine Development for LMICs
Release Date:
Review Process: Pfizer Internal
Research Vaccines All
Quality Improvement Grants to Support Development of Cardiac Amyloid Centers
Release Date:
Review Process: Pfizer Internal
Quality Improvement Rare Disease USA
Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease USA